Antibodies to the prion protein, PrP, represent a promising therapeutic approach against prion 22 diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern. Here we describe 23 scPOM-bi, a bispecific antibody designed to function as a molecular prion tweezer. scPOM-bi 24 combines the complementarity-determining regions of the neurotoxic antibody POM1 and the 25 neuroprotective POM2, which bind the globular domain (GD) and flexible tail (FT) respectively. 26
preventing prion or other factors from docking to it and ii) binding to the flexible tail to engage the 45 region of PrP necessary for neurotoxicity. 46 We also show that neurotoxic antibodies cause the formation of soluble PrP oligomers that cause 47 Introduction 52 Prions are the causative agent of sporadic, hereditary and iatrogenic forms of transmissible 53 spongiform encephalopathies, which afflict humans and broad spectrum of mammals and are 54 invariably fatal [1] [2] [3] . Whereas Bovine Spongiform Encephalopathy (the most prevalent prion 55 disease in the 1990s, also known as "Mad Cow" disease) has been largely defeated, Chronic 56
Wasting Disease, which affects deer, elk and moose, remains prominent in parts of the US, Canada, 57
South Korea and has recently reached Norway [4] . These findings are raising renewed concerns 58 about the contamination of the food chain. Transmission of infectious animal material to humans 59 causes variant Creutzfeldt-Jakob disease (vCJD). A common Met/Val polymorphism at codon 129 60 of the PRNP gene is assumed to be important in susceptibility of humans to prion infections, with 61 homozygous individuals (Met/Met and Val/Val) being overrepresented in collectives of CJD 62 patients [5] . The recent discovery of a case of vCJD in a 36-year-old man producing both M129 and 63 V129 variants of PrP, which is much more frequent in the population and is thought to conduce to a 64 disease developing more slowly, has led to suggestion that we might be facing a new wave of vCJD 65 cases [6] . 66
Human prion diseases continue to be intractable and are poorly understood at the molecular level. It 67 is firmly established that conversion of cellular prion protein (PrP C ) into a toxic, self-replicating 68 form (scrapie, PrP Sc ) leads to the formation of aggregates [2, 7] . How such aggregates induce 69 toxicity, however, is largely unknown. 70 Antibodies against PrP have been proposed as a valid therapeutic strategy against prion diseases, 71 much like antibodies targeting the amyloid-β protein are showing promise in clinical trials against 72
Alzheimer's disease (AD) [8, 9] . Furthermore, anti-PrP antibodies were shown to be protective in 73 preclinical models of AD [10] . On the other hand, recent literature reports [11] have highlighted 74 potential safety issues, since an epitope-dependent subset of anti-PrP antibodies have been found to 75 cause prion mediated neurodegeneration. 76
PrP has a structured globular domain (GD), whose general architecture is highly conserved amongst 77 mammals, and an unstructured N-terminal region, often referred to as flexible tail (FT). Several 78 antibodies against the globular domain were shown to elicit neuronal toxicity [11, 12] . The exact 79 epitope on the GD, rather than the binding affinity or other properties, appears to be the main 80 determinant of toxicity. One such neurotoxic antibody with intriguing properties, POM1, was 81 extensively characterized [11, 13] . POM1 binds with low nanomolar affinity to a discontinuous 82 epitope comprising the α1-α3 region of the GD. PrP expressing mice and cerebellar organotypic 83 cultured slices (COCS) exposed to POM1 show rapid neurotoxicity [11] . Intriguingly, toxicity was 84 prevented by a deletion of the octapeptide repeats in the FT, even if this deletion did not affect the 85 POM1 epitope. Antibodies against the FT, such as POM2, were also capable of preventing POM1-86 mediated toxicity, but only if administered before POM1. 87 POM1 and bona fide prions exert similar toxic effects such as neuronal cell loss, astrogliosis, 88 microgliosis and spongiform change. PrP Sc , the proteinase K-resistant form of prion protein, is used 89 as a surrogate marker for prions and believed to be the infectious agent [14] . In both POM1 and 90 prions, metabotropic glutamate receptors play an important role in downstream toxicity and 91 compounds that rescue POM1-induced toxicity also alleviate PrP Sc -induced toxicity [15, 16] . 92
Overall, the observations indicate that antibody binding to specific sites in the globular domain 93 triggers a toxic process, mediated by the FT, which converges with that initiated by infectious 94 prions. However, toxic prion antibodies do not generate prion infectivity [17] . The above leads us 95 to propose that the binding of POM1 to a "toxicity triggering site" might emulate the docking of 96 PrP Sc (or other toxic factors) to the GD. According to this hypothesis, a molecule that occupies the 97 POM1 binding site in the GD might prove beneficial by preventing interaction with PrP Sc and, 98 consequently, toxicity. 99
Here we designed a bispecific antibody formed by the POM1 variable region, which binds the GD, 100 and the POM2 variable region, which binds to the FT and was shown to prevent POM1-mediated 101 toxicity. We show here that the POM1-POM2 bispecific single chain antibody (called scPOM-bi), a 102 combination of the toxic POM1 and non-toxic POM2 antibodies, is capable of preventing prion 103 toxicity in COCS even when given 21 days post infection, when signs of prion pathology are 104 already visible [18] . POM1 forms soluble PrP-containing oligomers that cause toxicity to PrP 105 expressing cells. By contrast, delivery of scPOM-bi prevents formation of soluble oligomers. 106 scPOM-bi shows increased protection in comparison to the isolated POM2 or to a mixture of POM1 107 and POM2, despite having similar binding affinity, suggesting that simultaneous targeting of 108 globular domain and flexible tail might represent an optimized strategy for immunotherapy of prion 109 diseases. 110
111

Results
112
Design of scPOM-bi, a bispecific POM1-POM2 antibody 113
We fused the toxic antibody POM1 with POM2, capable of preventing its toxicity if administered 114 before POM1, by joining their variable regions in single chain format with a (GGGGS) x3 linker 115 commonly utilized in non-natural antibodies [19, 20] . We have had considerable success in using 116 this format to produce bispecific antibodies against various targets. Although the order of the 117 variable fragments and linker size might affect binding and efficacy, computational simulations 118 showed that the chosen design, with the POM1 moiety preceding POM2 and the chains arranged as 119 VL-VH-VH-VL, was compatible with binding to PrP. Indeed, the resulting bispecific nanobody, 120 scPOM-bi, was produced in E. coli and characterized to be functional, monomeric and folded with a 121 melting temperature of 75 °C (S1 Fig.) . We did not, therefore, explore the production of alternative 122 constructs. Computational docking and molecular dynamics simulations, based on the available 123 experimental structures of POM1 in complex with PrP globular domain [21] and POM2 bound to a 124 FT derived peptide [22] , indicate that the size and orientation of scPOM-bi is compatible with 125 bivalent engagement of PrP (Fig 1) . 126 127
scPOM-bi protects from prion toxicity when administered late after prion infection 128
When infected with prions, COCS faithfully mimic prion pathology and are easily accessible to 129 pharmacological manipulation [23] . In contrast to POM1, chronic treatment with scPOM-bi for 21 130 days did not produce observable toxicity in COCS despite comprising the toxic POM1 moiety ( Fig  131   2A ). Furthermore, simultaneous addition of the individuals POM1 and POM2 to COCS resulted in 132 neurotoxicity, indicating that the bispecific has different properties than the simple sum of its parts. 133
We added scPOM-bi to COCS from PrP C -overexpressing Tga20 mice infected with either RML6 134 prions (RML6 = passage 6 of the Rocky Mountain Laboratory strain, mouse-adapted scrapie prions) 135 or non-infectious brain homogenate (NBH) as a control. 45 days post infection (dpi), 136 immunohistochemical staining for NeuN, identifying neurons, showed widespread neuronal 137 degeneration in the presence of RML but not NBH. By contrast, treatment with scPOM-bi 138 prevented RML-induced neurotoxicity even when administered at 21 dpi ( Fig 2B and S2 Fig) . The 139 anti-FT antibody POM2 did not afford similar protection levels at 21 dpi, despite being used at 5-140 fold higher molarity than scPOM-bi ( Fig 2B) and having comparable binding affinity for PrP ( Fig  141   3 ). PrP Sc levels, detected by proteinase K-digestion of tissue inoculated with RML, remained 142 constant in prion-infected Tga20 COCS treated with scPOM-bi for 21days ( Fig 2C) , suggesting that 143 neuroprotection is not primarily mediated by reduced amounts of PrP Sc in RML infected COCS. 144 145 scPOM-bi binds with high affinity to globular domain and flexible tail of PrP 146 Surface plasmon resonance (SPR) assays showed that scPOM-bi binds PrP with low nanomolar 147 affinity, stronger than that of its individual single chain components due to avidity effects, resulting 148 in slower dissociation, when the two antigen binding sites are engaged (Fig 3) . Indeed, scPOM-bi 149 was found to bind to both a PrP construct lacking the FT and to one lacking the GD with affinity 150 similar to that of its individual components, scPOM1 and scPOM2 ( Fig 4A) . As a reference, the monomeric scPOM1:GD complex has an elliptical shape of ~7x5 nm according to the available x-ray structure [13] . The radius value is derived from 168 interpretation of DLS data using a spherical model which may or may not be appropriate for these 169 molecules. This, however, does not affect the following qualitative and comparative analysis of the 170 results. 171
When POM1 was added in vitro to a truncated version of mPrP, Δ mPrP(residues 90-230), lacking 172 the N-terminal FT, only monomeric species were found in solution. The disordered region of PrP, in 173 other words, was required for the formation of POM1-induced soluble aggregates just like POM1-174 induced neurotoxicity is abrogated in the absence of the FT. Notably, the soluble oligomers were 175 also not formed when mPrP was bound by the non-toxic POM2. Upon addition of scPOM-bi to 176 mPrP, instead, the presence of soluble oligomers are detected at the first observed time point (~5 177 minutes after complex formation) but these disappear with time ( Fig 4A) . 178
It was previously shown that POM1-induced toxicity is inhibited by the prior incubation of PrP with 179 POM2 [15] . Similarly, soluble oligomers were not formed when POM1 was added to a pre-formed 180 POM2:mPrP complex ( Fig 4A) . By contrast, addition of POM2 to pre-formed POM1:mPrP 181 complexes was not capable of preventing toxicity or eliminate the presence of soluble oligomers 182 ( Fig 4A) . 183
In contrast to POM2, scPOM-bi was able to eliminate soluble oligomers even when added 5 184 minutes after the formation of a POM1:mPrP complex, when DLS showed that soluble oligomers 185 were already present ( Fig 4A) . The difference was not due to the presence of two binding sites in In order to further characterize oligomers and insoluble aggregates through an independent method 206 we measured the size of mPrP:Ab complexes by confocal microscopy. Briefly, mPrP and antibody 207 were mixed in a test tube and, after 20 minutes, analyzed by DLS to characterize the aggregation 208 state. At that point the material was deposited on microscopy slides without centrifugation or other 209 clarification steps. The lowest resolvable structure in laser scanning confocal microscopy images in 210 our experimental settings is diffraction limited at ~120nm. Objects of smaller size are detected as 211 points but the size and diameter cannot be properly resolved or measured. The toxic POM1:mPrP 212 complexes formed smaller particles with average area of ~2.5 μm 2 . Statistically larger particles with 213 an average of ~6 μm 2 were detected for the non-toxic POM2 and scPOM-bi combinations ( Fig 4C) . 214 Furthermore, treatment of the mPrP:Ab complexes formed in vitro with 2μg/mL of Proteinase K 215 showed that species resistant to low PK concentrations were more abundant when mPrP was bound 216 by the toxic POM1 rather than POM2, scPOM-bi or when POM1 bound a PrP construct lacking the 217 FT ( Fig 4D) . 218
Overall, the above indicates that protective antibodies prevented the formation of soluble, partially 219 PK resistant oligomers whose formation requires the FT and is correlated with POM1 induced 220 neurotoxicity. The protective scPOM-bi bispecific antibody, but not POM2, was capable of 221 eliminating pre-formed POM1-induced soluble oligomers. 222
In order to test if the POM1-dependent soluble oligomers are indeed toxic, we first formed them in 223 vitro by mixing mPrP with the various antibodies and then added the material to CAD5 cells; after 224 48 hours the cellular toxicity was evaluated with standard propidium iodide staining and FACS 225 analysis ( Fig 5) . The scPOM1:mPrP soluble oligomers caused toxicity in PrP C -expressing CAD5 226 cells but not in PrP C knock-out (PrP -/-) CAD5. No toxicity was detected, instead, when scPOM1 227 was in complex with the truncated ΔmPrP 90-230 lacking the FT. Addition of the scPOM2:mPrP 228 complex resulted in no toxicity, as well. Intriguingly, addition of the scPOM-bi:mPrP material to 229 cells 10 minutes after complex formation resulted in toxicity, albeit lower than with scPOM1. 230 However, toxicity was not significant if the material was added 60 minutes after complex 231 formation. DLS shows that scPOM-bi forms soluble oligomers, much like POM1, in the initial 232 minutes after complex formation (possibly because some of the bispecific engages mPrP only with 233 the POM1 moiety, thus acting just like POM1) but these disappear with time. There is, in other 234 words, correlation between the presence of soluble oligomers and cellular toxicity. By contrast, 235 addition of the isolated scPOM-bi to CAD5 cells resulted in no toxicity, differently from POM1. A 236 possible interpretation is that formation of toxic scPOM-bi soluble oligomers requires local high 237 concentration of mPrP which is available in vitro but not in cells. Indeed, scPOM-bi not only lacked neurotoxicity, despite containing the toxic POM1 moiety, and in 254 contrast to simultaneous addition of POM1 and POM2 to COCS, but also protected organotypic 255 brain cultures from prion-induced neurodegeneration. Neuroprotection was evident even when 256 scPOM-bi was administered 21 days post infection, when signs of prion pathology were already 257 evident, suggesting that molecular tweezers may form the basis for a rational therapy of prion and 258 possibly other neurodegenerative diseases. scPOM-bi afforded stronger neuroprotection than 259 POM2, suggesting that the concomitant blockade of GD and FT is particularly effective against 260 prion toxicity. 261 POM1, but not POM2 or scPOM-bi, caused recombinant mPrP to form soluble oligomers resistant 262 to low concentration of proteinase K. Soluble oligomers were not formed when POM1 bound to an 263 N-terminally truncated construct lacking the FT, ΔmPrP 90-230 . There is a correlation between 264 oligomer formation and toxicity: neurotoxic antibodies or combinations (such as POM1) formed 265 soluble oligomers, whereas those that were unable to generate them (such as POM2 or the bispecific 266 tweezer described here) were innocuous or even protective in ex vivo cultured brain slices. the local PrP concentration in CAD5 cells is presumably lower. It is also worth noting that 279 treatment with isolated POM1 causes apparently lower toxicity than treatment with the same 280 amount of POM1:PrP soluble oligomers, further suggesting that the oligomers are relevant for 281 toxicity. The above observations indicate that the induction of oligomeric PrP forms may play a role 282 in POM1 toxicity. Since the antibodies that prevent oligomer formation were protective not only 283 against POM1 but also against prion infection, we suggest that these soluble oligomers might also 284 be involved in prion mediated toxicity. This interpretation is in agreement with the conjecture that 285 soluble aggregates are the primary toxic species driving diverse proteinopathies such as 286 from a toxic oligomerization to a non-toxic aggregation pathway. The fact that formation of PK 288 resistant material is not inhibited by scPOM-bi further corroborates the idea that toxicity, or 289 protection, is mediated by a different downstream event. There is evidence for similar mechanisms 290 in alpha-synuclein and Aβ, where non-toxic aggregates of size and conformation different from 291 those of toxic soluble oligomers were found [33] [34] [35] . Distinct tauopathies are linked to different 292 molecular conformers of aggregated Tau, as well [36] . Furthermore, PrP Sc conformers of different 293 size, compatible with what we observed by DLS, and shape were found in strains with different 294
properties and infectivity [37, 38] . 295
The scPOM-bi bispecific antibody, but not POM2, achieved the elimination of existing oligomers 296 from a solution of pre-formed POM1:mPrP complexes. scPOM-bi was also more effective than 297 POM2 at blocking prion mediated toxicity. One possibility is that, by bridging across two PrP 298 molecules, scPOM-bi might favor the elongation of preexisting soluble oligomers, leading to larger, 299 non-toxic species (Fig 6) . However POM2-IgG can also bridge across two PrP molecules and yet it 300 is less protective than scPOM-bi and cannot eliminate the POM1-induced soluble aggregates 301 despite comparably high affinity. Engagement of the globular domain appears to be important, 302 either by inhibiting the binding of other molecules to a toxicity triggering site or by locking PrP GD 303 in a non-toxic conformation. 304
Indeed, simultaneous targeting of GD and FT by the bispecific antibody described here resulted in 305 more potent protection, even when given at late timepoints, than simple targeting of the FT. We 306 conclude that the strategy delineated here may be exploited for the development of effective 307 immunotherapeutics against prion and possibly other diseases. In order to characterize both soluble oligomers and insoluble aggregates we formed the mPrP:Ab 361 complexes in vitro and deposited the resulting material on microscopy slides. Confocal microscopy indicates that toxic antibody combinations (e.g. POM1:mPrP or POM1:mPrP followed by POM2, 363 red and orange) generate species with smaller average size than protective antibody combinations. 364
The surface area of the detected species is reported on the y axis, the horizontal line represents the 365 average. Differences can also be appreciated by visual inspection of the confocal microscopy 366 images (S4 Fig -scPOM1 :mPrP n=166, scPOM2:mPrP n=1136, scPOM-bi:mPrP n=204, 367 scPOM1:mPrP then scPOM2 n=444, scPOM2:mPrP then scPOM1 n=74 and scPOM1:mPrP then 368 scPOM-bi n=1767). D) The soluble oligomers generated by POM1 showed increased resistance to Prnp. Amplified products were cloned into the pCR-Blunt II-TOPO plasmid (Invitrogen) and 10 425 colonies per clone were sequenced by Sanger sequencing. Herein, #C2 showed four different 426 mutations, i.e., three deletions and one insertion, while #C12 showed two different deletions 427 proximal to the PAM (S7D Fig.) . These results indicate multiploidy to be more likely in #C2 than in 428 #C12, hence all further experiments are performed with the CAD5 Prnp -/clone #C12. Biolabs), 70 µl ddH 2 O. Reaction mix was heated for 4 min at 95°C on a heating block ThermoStat 438 (Eppendorf), then the heating block was turned off and the reaction was allowed to proceed for 30 439 min on the block and was then put at 4°C. Golden Gate assembly [45] was used in order to clone 440 the double-stranded DNA Oligomers into the MLM3636 plasmid, using the following reaction: 441 442 This reaction was put on a thermocycler using the following conditions: 443 was undertaken using the primers Prn-ko F1 (5' -TGC AGG TGA CTT TCT GCA TTC TGG -3' The structure of scPOM-bi used in the computational simulations was modeled on the experimental 515 structures of the POM1:PrP 124-225 complex (PDB code 4H88) and POM2:octarepeat-peptide (PDB 516 code: 4J8R) complexes. After initial superposition of the POM1 and POM2 moiety on the structure 517 of one (for intramolecular binding models) or two (for intermolecular binding models) PrP 518 molecules, the linker joining the two scFv was manually built. The system was then subjected to 519 100ns of fully atomistic molecular dynamics simulations (MD) to obtain an energetically favorable 520 and stable conformation. 521
In all cases, the system was initially set up and equilibrated through standard MD protocols: 522 proteins were centered in a triclinic box, 0.2nm from the edge, filled with SPCE water model and 523 0.15M Na+Cl-ions using the AMBER99SB-ILDN protein force field. Energy minimization was 524 performed in order to let the ions achieve a stable conformation. Temperature and pressure 525 equilibration steps, respectively at 298°K and 1 Bar, of 100ps each were then performed before 526 performing 300ns molecular dynamics simulations with the above mentioned force field. MD The size of PrP either alone or in complex with different antibodies was estimated by Dynamic 572
Light Scattering (DLS) at 25°C using a "DynaPro -NanoStar" instrument (WYATT) in 10µL at a 573 concentration of 5µM. The PrP:antibody ratio was 1:1 for monovalent binding (e.g. scF v ) and 2:1 for bivalent binding species (e.g. full IgG). Readings were taken 2, 5, 10, 20 and 30 minutes after 575 complex formation. When evaluating addition of a second antibody (e.g. forming a PrP/scPOM1 576 complex and then adding scPOM-bi), PrP and the first antibody were pre-mixed for 5 minutes and 577 then the second antibody was added. Each time point measurement was performed by 10 repetitions 578 of 5 seconds signal integration. A Rayleigh sphere model was used for size estimation. At least 3 579 repetitions of the same experiment were performed on different, freshly prepared samples. Before 580 complex formation, all samples were dialyzed together in 20mM HEPES pH 7.2 150mM NaCl, 581 centrifuged at 21000g and filtered with 0.22µm filters before measurement. Statistics: all 582 experiments are shown as mean with standard error of the mean (SEM). 583 584
Precipitation assays 585
Quantification of soluble PrP either alone or in complex with different antibodies was performed 586 using SDS-PAGE and either comassie staining (for PrP alone and in complex with scFv) or western 587 blot (for PrP/IgG complexes). The precipitation assays were run in parallel to DLS assays in the 588 conditions indicated above. Samples were centrifuged for 2 minutes at 21000g at 4°C. 25µL of 589 supernatant was collected, mixed with equal volume of sample buffer and loaded on polyacrylamide 590 gel (4% Stacking -12% running). For comassie staining, SDS-PAGEs were left 10 minutes in 591 2.5g/L Comassie Brilliant Blue G-250 (Sigma) 40% Methanol and 10% Glacial Acetic Acid and 592 then destained using 70% ddH20, 20% Methanol and 10% Glacial Acetic Acid for 1hour at least. 593 Gels were then acquired using ImageQuant LAS 4000 (GE Healthcare) according to standard 594 procedures. For western blot, proteins from SDS-PAGE were transferred onto PVDF membranes, 595 blocked in TBS-Tween20 10% Milk for 10 minutes at RT and probed with an antibody against PrP 596 (POM19 mouse IgG 1µg/mL in TBS-Tween20 for 16 hours at 4°C) that does not compete with 597 either scPOM1, scPOM2 and scPOM-bi. The primary antibody was detected using a goat anti-598
Mouse-HRP conjugated antibody (1:10000 in TBS-Tween20 for 1hour at RT, from ThermoFisher) 599 and developed using Pierce™ ECL Western Blotting Substrate (ThermoFisher).
für Lebensmittelsicherheit und Veterinärwesen BLV. Body weights were measured weekly. All 627 animal protocols and experiments performed were specifically approved for this study by the 628 responsible institutional animal care committee, namely the Animal Welfare Committee of the 629 Canton of Zürich (permit numbersVersuchstierhaltung 123, ZH139/16 and 90/2013). All efforts 630 were made to minimize animal discomfort and suffering. 631 
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